{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:06:51Z","timestamp":1790816811461,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jcyt.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T02:55:56Z","timestamp":1623207356000},"page":"1060-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Consensus International Council for Commonality in Blood Banking Automation\u2013International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells"],"prefix":"10.1016","volume":"23","author":[{"given":"Sowmya","family":"Viswanathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Le Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Moniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald G.","family":"Phinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew M.","family":"Szczepiorkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Tarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2021.04.009_bib0001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0003","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0004","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jca.20145","article-title":"Standards for the terminology and labeling of cellular therapy products","volume":"22","author":"Ashford","year":"2007","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0006","series-title":"Standard Terminology for Medical Products of Human Origin","author":"Rice","year":"2021"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0007","series-title":"Nomenclature Scheme For Cell Therapy Products (CTP)","year":"2015"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0008","unstructured":"Available Products. Alliance for Regenerative Medicine n.d. https:\/\/alliancerm.org\/available-products\/(accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0009","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0010","unstructured":"European Medicines Agency. Alofisel. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alofisel. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0011","unstructured":"Stempeutics Reserch Pvt Lts, Stempeucell, Stempeutron, Stempeucare, Cutisera, Stem Cells n.d. https:\/\/www.stempeutics.com\/clinical-trials-CLI.html. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5966\/sctm.2016-0237","article-title":"Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy","volume":"6","author":"Gupta","year":"2017","journal-title":"STEM CELLS Translational Medicine"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0013","unstructured":"Government of Canada HC. Drug Product Database Online Query 2012. https:\/\/health-products.canada.ca\/dpd-bdpp\/info.do?lang=en&code=87195. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0014","unstructured":"Medsafe. Product Detail n.d. https:\/\/medsafe.govt.nz\/regulatory\/ProductDetail.asp?ID=15063. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0015","unstructured":"Products | JCR Pharmaceuticals Co., Ltd. n.d. https:\/\/www.jcrpharm.co.jp\/en\/site\/en\/biopharmaceutical\/product_tem.html. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0016","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/d41586-019-00178-x","article-title":"Japan's approval of stem-cell treatment for spinal-cord injury concerns scientists","volume":"565","author":"Cyranoski","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0017","unstructured":"MEDIPOST. CARTISTEM\u00ae. n.d. http:\/\/www.medi-post.com\/cartistem\/. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0018","article-title":"Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children","author":"Limited","year":"2020","journal-title":"GlobeNewswire News Room"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0019","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41556-019-0308-3","article-title":"Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells","volume":"21","author":"Nakahara","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/stem.3077","article-title":"Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells","volume":"38","author":"M\u00e9nard","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0021","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/sctm.17-0167","article-title":"Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease","volume":"7","author":"Ringden","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0022","doi-asserted-by":"crossref","first-page":"17986","DOI":"10.3390\/ijms140917986","article-title":"Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy","volume":"14","author":"Jin","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41536-019-0070-y","article-title":"Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential","volume":"4","author":"Kehl","year":"2019","journal-title":"Npj Regenerative Medicine"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0024","doi-asserted-by":"crossref","first-page":"17765","DOI":"10.1038\/s41598-018-36057-0","article-title":"Chromatin accessibility identifies diversity in mesenchymal stem cells from different tissue origins","volume":"8","author":"Ho","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3389\/fimmu.2019.00619","article-title":"Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model","volume":"10","author":"Gr\u00e9goire","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0026","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular Mesenchymal Stromal\/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0027","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","article-title":"Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study","volume":"26","author":"Bloor","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fcell.2020.00149","article-title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles: Challenges in Clinical Applications","volume":"8","author":"Gowen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0029","unstructured":"ISO. ISO\/WD TS 22859: Biotechnology\u2014Biobanking\u2014Requirements for human mesenchymal stromal cells derived from umbilical cord tissue. https:\/\/www.iso.org\/cms\/render\/live\/en\/sites\/isoorg\/contents\/data\/standard\/07\/40\/74052.html. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0030","unstructured":"ISO. ISO\/CD 24651: Biotechnology\u2014Biobanking\u2014Requirements for human mesenchymal stromal cells derived from bone marrow. https:\/\/www.iso.org\/cms\/render\/live\/en\/sites\/isoorg\/contents\/data\/standard\/07\/91\/79141.html. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0031","unstructured":"World Health Organization. WHO\/BS\/2019.2376 Collaborative Study to assess the suitability of the candidate WHO IRR for MSC identity (for flow cytometry) for advance therapies https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-2019.2376. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0032","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/scd.2013.0591","article-title":"Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation","volume":"23","author":"Viswanathan","year":"2014","journal-title":"Stem Cells and Development"},{"key":"10.1016\/j.jcyt.2021.04.009_bib0033","unstructured":"Mesoblast. Annual General Meeting November 24, 2020. http:\/\/investorsmedia.mesoblast.com\/static-files\/1f2a6a44-05ec-48a5-bcdf-ed244220e221. (accessed February 10, 2021)."},{"key":"10.1016\/j.jcyt.2021.04.009_bib0034","unstructured":"BioSpace. Athersys Preps MultiStem\u00ae Stroke Therapy for Approval Under Japan's RegenMed Law. https:\/\/www.biospace.com\/article\/athersys-preps-multistem-stroke-therapy-for-approval-under-japan-s-regenmed-law-\/. (accessed February 10, 2021)."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921006447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921006447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:44:57Z","timestamp":1761443097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324921006447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1465324921006447"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.04.009","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus International Council for Commonality in Blood Banking Automation\u2013International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}